Bristol-Myers Squibb Release: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B)

Press/Media: Press / Media

PeriodApr 27 2015

Media coverage

1

Media coverage

  • TitleBristol-Myers Squibb Release: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B)
    Media name/outletBioSpace
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad